Relief Therapeutics Holding AG (RLFTF)

[PennyWorld]

Yes, and hear is another perspective from an investor who is also 'in the know' in the medical space. There's a small bit of redundancy though with the other posts.

My thinking too is that now with JJ being demoted to Chief Scientist, we aren't going to see the flurry of pump PRs and web site postings that we have seen in the past coming out of NRXP. If any of this assessment is true, JJ would normally be pumping out this perspective in a PR. I think NRXP is playing it safe with their PRs considering the ongoing law suit.

-------------
IG — Today at 1:45 AM
In my opinion, it is important to note once again that the study was stopped due to a secondary endpoint. Now the primary endpoint "Ordinal Scale of Recovery" can be analyzed. All these factors incl. lung function in the first days etc. are all secondary endpoints which are now also analyzed... (there are about 25 - 30 secondary endpoints) it would be possible that the NIH study shows exactly the same result as the Indian trial.

But now that we don't have SARS anymore with Omrikon, the pure ARDS arm of the trial has been closed while Remdesivir of course has a broader scope. In brief there was no need to keep the study open to treat uniquely the SARS. It just consumes money, does not solve an acute patient problem and prevents the NIH to analyze the data being ready for next winter… don’t you get it ? It was the logical conclusion to close the Aviptadil Arm and keep the Remdesivir arm open. This is no conspiracy this is just intelligent behavior.

Now let's wait and see one step at a time. Again medicine needs good ARDS drugs and the NIH will be looking at this closely. Some may still surprised here .... (not me)